Biotech startup OccuRx has raised $16 million to fund clinical phase studies for its oral therapy to treat chronic kidney disease (CKD), a leading cause of death.
The round was jointly led by Brandon BioCatalyst and Uniseed and also includes…
Stoic VC
https://stoicvc.com.au/wp-content/uploads/2022/11/7_1000x.jpg7501000Stoic VChttps://stoicvc.com.au/wp-content/uploads/2023/04/Screen-Shot-2023-04-25-at-5.44.30-pm-300x137.pngStoic VC2022-09-13 13:12:462022-11-13 13:14:31Occurx raises $16 million, progresses into clinical trials for chronic kidney disease (CKD)
